NCT01806337View on ClinicalTrials.gov

CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

July 31, 2006

Study Completion Date

February 28, 2011

Conditions
Peripheral T-Cell Lymphoma
Interventions
DRUG

Alemtuzumab

Consolidation after CHOP induction

All Listed Sponsors
lead

University of Göttingen

OTHER

NCT01806337 - CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma | Biotech Hunter | Biotech Hunter